Summary & Overview
HCPCS C9073: Brexucabtagene Autoleucel CAR‑T Therapy
HCPCS Level II code C9073 represents brexucabtagene autoleucel, an autologous anti‑CD19 CAR‑T cell therapeutic dose that includes leukapheresis and dose preparation. This code captures a complex, high-cost cellular immunotherapy used in specialized treatment settings and is significant nationally for its implications on oncology care delivery, specialty pharmacy coordination, and payer coverage policies.
Key payers discussed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how these payers approach coverage and reimbursement for CAR‑T therapies, common billing considerations tied to bundled service elements, and typical sites of care where the service is delivered.
Readers will learn clinical context for the therapy, the components bundled under the code, expected sites of service, and the types of benchmarks and policy updates that affect access and payment. The report also summarizes common modifiers used in practice and highlights areas where payers and providers often need clear documentation and coding alignment. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9073 describes brexucabtagene autoleucel, an autologous CAR‑T cell therapy providing up to 200 million anti‑CD19 CAR‑positive viable T cells per therapeutic dose. The code includes leukapheresis and dose preparation procedures as part of the single therapeutic dose delivery.
Service type: Cellular immunotherapy (CAR‑T therapy), inclusive of leukapheresis and dose preparation
Typical site of service: Inpatient hospital or specialized ambulatory infusion center with cellular therapy capabilities, where leukapheresis, cell processing, and therapeutic administration occur.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory B‑cell malignancy (for example, relapsed diffuse large B‑cell lymphoma) who has exhausted standard therapies and is being evaluated for autologous anti‑CD19 CAR T‑cell therapy. The clinical workflow begins with hematology/oncology referral and comprehensive eligibility assessment (disease status, organ function, performance status, infectious disease screening). After consent, leukapheresis is performed to collect autologous peripheral blood mononuclear cells. Collected cells are shipped to a GMP facility for manufacturing of Brexucabtagene autoleucel product (up to 200 million viable CAR‑positive T cells). Prior to infusion, the patient typically receives lymphodepleting chemotherapy (for example, fludarabine/cyclophosphamide) administered in the inpatient or outpatient oncology infusion center. On the day of dosing, the manufactured CAR T product is received, undergoes dose preparation and release testing, and is infused under close monitoring for cytokine release syndrome and neurotoxicity. Post‑infusion care includes inpatient observation or close outpatient monitoring, laboratory surveillance, and management of potential complications. Billing for this therapeutic dose includes leukapheresis collection, manufacturing, dose preparation procedures, and the CAR T infusion as described by code C9073.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |